Infantile Serine Biosynthesis Defect Due to Phosphoglycerate Dehydrogenase Deficiency: Variability in Phenotype and Treatment Response, Novel Mutations, and Diagnostic Challenges. (May 2017)

• Record Type: Journal Article
• Authors: Benke, Paul J.; Hidalgo, Ryan J.; Braffman, Bruce H.; Jans, Judith; Gassen, Koen L.I. van; Sunbul, Rawda; El-Hattab, Ayman W.
• Is Part Of: Journal of child neurology. Volume 32:Number 6(2017:Jun.)
• Page Start: 543
• Page End: 549
• Publication Date: 2017-05
• Subjects: PGDH -- Neu-Laxova syndrome -- microcephaly -- spasticity -- seizures; Nervous system -- Diseases -- Periodicals; 618.928
• DOI: 10.1177/0883073817690094
• Languages: English
• ISSNs: 0883-0738

Abstract

Serine biosynthesis defects can present in a broad phenotypic spectrum ranging from Neu-Laxova syndrome, a lethal disease with multiple congenital anomalies at the severe end, to an infantile disease with severe psychomotor retardation and seizures as an intermediate phenotype, to a childhood disease with intellectual disability at the mild end. In this report we present 6 individuals from 3 families with infantile phosphoglycerate dehydrogenase (PGDH) deficiency who presented with psychomotor delay, growth failure, microcephaly, and spasticity. The phenotype was variable with absence of seizures in 2 sisters in family 1 and 1 infant in family 2 and seizures with pronounced happy affect in 3 sisters in family 3. The initiation of serine treatment had pronounced effect on seizures and spasticity in the sisters in family 3, but minimal developmental effects on the children in families 1 and 2. With such phenotypic variability, the diagnosis of PGDH deficiency can be challenging.